当前位置: 首页 > 详情页

The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Cardiovascular, Beijing Tiantan Hospital, Capital Medical University, No. 119 South 4th Ring West Road, Beijing 100070, Fengtai District, China. [2]Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
出处:
ISSN:

关键词: Cardio embolism Cerebral microbleeds Nonvalvular atrial fibrillation Antithrombotic therapy

摘要:
BackgroundThe impact of cerebral microbleeds on the safety of antithrombotic therapy has recently received considerable attention. We investigated the safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism caused by nonvalvular atrial fibrillation.MethodsThis retrospective study enrolled patients with acute cardiogenic cerebral embolism due to nonvalvular atrial fibrillation in the stroke unit of the Department of Neurology at the Beijing Tiantan Hospital, the Capital Medical University, from January 2015 to January 2018. General clinical data, magnetic resonance imaging data, and data regarding the use of antithrombotic medications were collected. The main adverse events were cerebral hemorrhage and all-cause death.ResultsAccording to the susceptibility-weighted imaging sequence, patients were divided into a cerebral microbleeds group and a non-cerebral microbleeds group. Patients with cerebral microbleeds were more likely to be male and to have a history of hypertension and diabetes, and they were less likely to have received anticoagulant therapy (49.1% vs. 71.3%, P=0.001). However, no significant differences were found in the event-free time, the occurrence of cerebral hemorrhage events and all-cause death. Cox regression analysis showed that the risk of all-cause death in patients with a cerebral hemorrhage history and cerebral microbleeds increased 2.773-fold (HR=2.773, 95%CI 1.056-7.280, P=0.019), and the risk of a cerebral hemorrhage event in patients with cerebral microbleeds and a hypertension history (HR=3.451, 95%CI 1.947-6.119, P=0.045) or a cerebral hemorrhage history (HR=2.443, 1.078-5.536, P=0.006) was increased 3.451-fold and 2.443-fold, respectively.ConclusionsAntithrombotic therapy in patients with CMBs and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation did not have increased risks of a cerebral hemorrhage event and all-cause death. CMBs were probably not a crucial predictor of whether patients were prescribed antithrombotic medicine. Patients with CMBs and a hypertension history or cerebral hemorrhage history should receive a close follow-up after antithrombotic therapy.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 心脏和心血管系统
JCR分区:
出版当年[2017]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
最新[2023]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Department of Cardiovascular, Beijing Tiantan Hospital, Capital Medical University, No. 119 South 4th Ring West Road, Beijing 100070, Fengtai District, China.
通讯作者:
通讯机构: [1]Department of Cardiovascular, Beijing Tiantan Hospital, Capital Medical University, No. 119 South 4th Ring West Road, Beijing 100070, Fengtai District, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院